Other Information
−Removed: (c) During the three months ended September 30, 2023, the following officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense of Rule 10b5–1(c) under the Securities Exchange Act of 1934:
−Removed: Vijay Iyengar , our Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy , adopted a trading plan on September 15, 2023 providing for the sale of up to an aggregate of 50,672 shares of our common stock until July 31, 2024.
−Removed: Thomas Tray , our Vice President, Chief Accounting Officer , adopted a trading plan on September 12, 2023 providing for the sale of up to an aggregate of 1,277 shares of our common stock until September 12, 2024.
−Removed: During the three months ended September 30, 2023, no director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), other than as set forth above.
+Added: (c) During the three months ended March 31, 2024, the following officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense of Rule 10b5–1(c) under the Securities Exchange Act of 1934:
+Added: Steven Stein , our Executive Vice President and Chief Medical Officer , adopted a trading plan on February 20, 2024 providing for the sale of up to an aggregate of 20,147 shares of our common stock until December 31, 2024.
+Added: Barry Flannelly , our Executive Vice President and General Manager, North America , adopted a trading plan on February 20, 2024 providing for the sale of up to an aggregate of 52,931 shares of our common stock until December 31, 2024.
+Added: Thomas Tray , our Vice President, Chief Accounting Officer , adopted a trading plan on March 7, 2024 providing for the sale of up to an aggregate of 1,093 shares of our common stock until June 28, 2024.
+Added: During the three months ended March 31, 2024, no director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), other than as set forth above.
Number Description of Document
+Added: 10.1 Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 (File No.
+Added: 333-277043)).
+Added: 10.2 Form of Global Nonstatutory Stock Option Agreement for Executive Officers under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (File No.
+Added: 333-277043)).
+Added: 10.3 Form of Global Restricted Stock Unit Agreement under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.3 to the Company’s Registration Statement on Form S-8 (File No.
+Added: 333-277043)).
+Added: 10.4 Form of Performance Share Award Agreement under the Incyte Corporation 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.4 to the Company’s Registration Statement on Form S-8 (File No.
+Added: 333-277043)).
31.1* Rule 13a-14(a) Certification of Chief Executive Officer .
18 unchanged sentences
INCYTE CORPORATION
−Removed: October 31, 2023
+Added: April 30, 2024
/s/ HERVÉ HOPPENOT
Hervé Hoppenot
−Removed: Chairman, President, and Chief Executive Officer
+Added: President, and Chief Executive Officer
(Principal Executive Officer)
−Removed: October 31, 2023
+Added: April 30, 2024
/s/ CHRISTIANA STAMOULIS
Christiana Stamoulis
−Removed: Chief Financial Officer
+Added: Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.